Anagenics Limited (AN1.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 03:33PM AEDT
| Previous close | 0.0200 |
| Open | 0.0230 |
| Bid | 0.0220 x N/A |
| Ask | 0.0250 x N/A |
| Day's range | 0.0220 - 0.0230 |
| 52-week range | 0.0190 - 0.0510 |
| Volume | |
| Avg. volume | 75,957 |
| Market cap | 4.868M |
| Beta (5Y monthly) | -0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0240 |
| Earnings date | 13 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for the study of the anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) in treating pediatric and young adult patients with relapsed
© 2023 Yahoo. All rights reserved.
